Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RePERSO: Regorafenib Dose Personalization in mCRC
NCT04874207Phase 4Completed
- Sponsor
- CHU Rennes
- Start
- Oct 2021
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of regorafenib in colorectal cancer (metastatic) (mCRC), sponsored by CHU Rennes. Started Oct 2021; status: completed.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT04874207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04874207.